Business
-
Inhalation Sciences (ISAB) announced that it has sold all of its remaining shares in its spinoff Ziccum AB, a spray drying specialist, for a total of approximately SEK 21.2 million. In May 2019, ISAB announced that… Read more . . .
-
Tech start-up Sensory Cloud has acquired an exclusive worldwide license for Pulmatrix salt formulations PUR 003 and PUR 006 (NasoCalm), for purposes of “OTC nasal delivery to potentially reduce the pathogenic risk and transmissibility of… Read more . . .
-
TFF Pharmaceuticals said that it has entered into a 3-year Cooperative Research and Development Agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) for development of dry powder vaccines against alphaviruses such as… Read more . . .
-
TFF Pharmaceuticals has announced a research collaboration deal with the University of Georgia’s Center for Vaccines and Immunology (CVI) and with the University of Texas at Austin (UT Austin) for testing of dry powder universal influenza vaccines formulated using TFF’s… Read more . . .
-
Third Pole Therapeutics has announced a deal with Chiesi Farmaceutici giving Chiesi global rights to develop and commercialize Third Pole’s tankless inhaled nitric oxide (iNO) delivery system for the treatment of infants with hypoxic respiratory… Read more . . .
-
Savara announced that it has acquired global development and commercialization rights to Apulmiq (Linhaliq) inhaled liposomal ciprofloxacin from Grifols. According to Savara, the deal includes an upfront payment to Grifols and regulatory milestone payments if… Read more . . .
-
The University of Wisconsin–Madison has announced that virologists from the university have partnered with vaccine companies FluGen and Bharat Biotech on development of an intranasal vaccine against unique vaccine against SARS-CoV-2 for the prevention of… Read more . . .
-
Swiss biotech Neurimmune has partnered with German mRNA specialist Ethris to develop inhaled mRNA-encoded neutralizing anti-SARS-CoV-2 antibodies for the treatment of Covid-19, the companies said. The goal is to begin clinical manufacturing of the drug… Read more . . .
-
Austrian biotech APEPTICO said that it has signed a grant agreement with the European Commission to accelerate the availability of the company’s solnatide (AP301), an inhaled peptide, available for treatment of patients with severe COVID-19. APEPTICO… Read more . . .
-
Windtree Therapeutics has announced that Lee’s Pharmaceutical Holdings will provide funding for a Phase 2b study of Windtree’s Aerosurf inhaled KL4 surfactant for the treatment of respiratory distress syndrome in preterm infants. Windtree will repay… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden